Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 15, 2021
Narrative Medicine to integrate patients', caregivers' and clinicians' migraine experiences: the DRONE multicentre projectMaria Clara Tonini, Alessandra Fiorencis, Rosario Iannacchero, et al.
The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
European Journal of Neurology|November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life studyFabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Journal of Neurology|June 28, 2022
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experienceClaudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
The Journal of Headache and Pain|March 23, 2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 studyPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 17, 2024
Retrospective analysis of a tertiary care centre of sex differences in risk factors, aetiology and short-term clinical outcome after revascularization treatment in young adults' ischemic strokeRosaria Renna, Gionata Spagnoletti, Mariana Rippa, et al.
Neurology and Therapy|March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 StudyPiero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Neurology and Therapy|June 9, 2026
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III StudyPiero Barbanti, Cinzia Aurilia, Massimo Filippi, et al.
Frontiers in Neurology|January 3, 2022
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in MenRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
The Journal of Headache and Pain|March 20, 2022
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen studyRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
Pageof 4